Drug intelligence / Profile preview

5-fluorouracil + cyclophosphamide + doxorubicin + methotrexate + prednisone + tamoxifen + vinblastine + vincristine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination of eight different drugs, each with its own mechanism of action. The combination includes: - 5-fluorouracil: An antimetabolite that stops cells from making and repairing DNA - Cyclophosphamide: An alkylating agent that stops cancer cells from reproducing - Doxorubicin: An anthracycline that stops cancer cells from making DNA and interferes with DNA repair enzymes - Methotrexate: An antimetabolite that inhibits dihydrofolate reductase - Prednisone: A corticosteroid with anti-inflammatory and immunosuppressive properties - Tamoxifen: A selective estrogen receptor modulator - Vinblastine: A vinca alkaloid that inhibits microtubule assembly - Vincristine: A vinca alkaloid that disrupts microtubules Various smaller combinations of these drugs (particularly FAC/CAF and CMF) are used in breast cancer treatment.

Targets

ER (Estrogen receptor)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on 5-fluorouracil + cyclophosphamide + doxorubicin + methotrexate + prednisone + tamoxifen + vinblastine + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + doxorubicin + methotrexate + prednisone + tamoxifen + vinblastine + vincristine.

Explore the full profile